Patents by Inventor Kathrine Osborn Lorenz

Kathrine Osborn Lorenz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ESTERS FOR TREATMENT OF OCULAR INFLAMMATORY CONDITIONS
    Publication number: 20210379005
    Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. Anti-inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g.
    Type: Application
    Filed: August 20, 2021
    Publication date: December 9, 2021
    Inventors: Annabelle Gallois-Bernos, Frank F. Molock, JR., Carrie L. Davis, Kathrine Osborn Lorenz, James K. Young, Kristy L. Canavan, Fang Lu
  • Esters for treatment of ocular inflammatory conditions
    Patent number: 11096919
    Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: August 24, 2021
    Assignee: Johnson & Johnson Vision Care, Inc.
    Inventors: Annabelle Gallois-Bernos, Frank F. Molock, Jr., Carrie L. Davis, Kathrine Osborn Lorenz, James K. Young, Kristy L. Canavan, Fang Lu
  • Esters for Treatment of Ocular Inflammatory Conditions
    Publication number: 20200222357
    Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. Anti-inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g.
    Type: Application
    Filed: March 26, 2020
    Publication date: July 16, 2020
    Inventors: Annabelle Gallois-Bernos, Frank F. Molock, JR., Carrie L. Davis, Kathrine Osborn Lorenz, James K. Young, Kristy L. Canavan, Fang Lu
  • ESTERS FOR TREATMENT OF OCULAR INFLAMMATORY CONDITIONS
    Publication number: 20190328698
    Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.
    Type: Application
    Filed: July 2, 2019
    Publication date: October 31, 2019
    Inventors: Annabelle Gallois-Bernos, Frank F. Molock, JR., Carrie L. Davis, Kathrine Osborn Lorenz, James K. Young, Kristy L. Canavan, Fang Lu
  • Ophthalmic compositions comprising polyether substituted polymers
    Patent number: 10441533
    Abstract: The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: October 15, 2019
    Assignee: Johnson & Johnson Vision Care, Inc.
    Inventors: Frank Molock, Kathrine Osborn Lorenz, Shivkumar Mahadevan
  • Esters for treatment of ocular inflammatory conditions
    Patent number: 10383839
    Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: August 20, 2019
    Assignee: Johnson & Johnson Vision Care, Inc.
    Inventors: Annabelle Gallois-Bernos, Frank F. Molock, Jr., Carrie L. Davis, Kathrine Osborn Lorenz, James K. Young, Kristy L. Canavan, Fang Lu
  • OPHTHALMIC COMPOSITIONS COMPRISING POLYETHER SUBSTITUTED POLYMERS
    Publication number: 20180064642
    Abstract: The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300.
    Type: Application
    Filed: November 14, 2017
    Publication date: March 8, 2018
    Inventors: Frank Molock, Kathrine Osborn Lorenz, Shivkumar Mahadevan
  • Ophthalmic compositions comprising polyether substituted polymers
    Patent number: 9849081
    Abstract: The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: December 26, 2017
    Assignee: Johnson & Johnson Vision Care, Inc.
    Inventors: Frank Molock, Kathrine Osborn Lorenz, Shivkumar Mahadevan
  • OPHTHALMIC COMPOSITIONS COMPRISING POLYETHER SUBSTITUTED POLYMERS
    Publication number: 20170157037
    Abstract: The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300.
    Type: Application
    Filed: February 16, 2017
    Publication date: June 8, 2017
    Inventors: Frank Molock, Kathrine Osborn Lorenz, Shivkumar Mahadevan
  • Ophthalmic compositions comprising polyether substituted polymers
    Patent number: 9606263
    Abstract: The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: March 28, 2017
    Assignee: Johnson & Johnson Vision Care, Inc.
    Inventors: Frank Molock, Kathrine Osborn Lorenz, Shivkumar Mahadevan
  • OPHTHALMIC COMPOSITIONS COMPRISING POLYETHER SUBSTITUTED POLYMERS
    Publication number: 20170042933
    Abstract: The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300.
    Type: Application
    Filed: October 27, 2016
    Publication date: February 16, 2017
    Inventors: Frank Molock, Kathrine Osborn Lorenz, Shivkumar Mahadevan
  • OPHTHALMIC COMPOSITIONS COMPRISING POLYETHER SUBSTITUTED POLYMERS
    Publication number: 20160158272
    Abstract: The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300.
    Type: Application
    Filed: February 16, 2016
    Publication date: June 9, 2016
    Inventors: Frank Molock, Kathrine Osborn Lorenz, Shivkumar Mahadevan
  • Ophthalmic compositions comprising polyether substituted polymers
    Patent number: 9297928
    Abstract: The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and linear or branched polyether pendant groups having a molecular weight of at least about 300.
    Type: Grant
    Filed: November 22, 2004
    Date of Patent: March 29, 2016
    Assignee: Johnson & Johnson Vision Care, Inc.
    Inventors: Frank Molock, Kathrine Osborn Lorenz, Shivkumar Mahadevan
  • ESTERS FOR TREATMENT OF OCULAR INFLAMMATORY CONDITIONS
    Publication number: 20130005805
    Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.
    Type: Application
    Filed: June 13, 2012
    Publication date: January 3, 2013
    Inventors: Annabelle Gallois-Bernos, Frank F. Molock, JR., Carrie L. Davis, Kathrine Osborn Lorenz, James K. Young, Kristy L. Canavan, Fang Lu
  • Contact lenses
    Patent number: 6454409
    Abstract: Contact lenses that have a back edge designed so that the flat portion of the edge does not rest on the wearer's conjunctiva are provided. The lenses of the invention exhibit good lens handling as well as excellent on-eye comfort and movement.
    Type: Grant
    Filed: August 15, 2000
    Date of Patent: September 24, 2002
    Assignee: Johnson & Johnson Vision Care, Inc.
    Inventors: Kathrine Osborn Lorenz, Timothy A. Clutterbuck, Brian S. Armitage, Susan B. Orr